Hemangiol (Propranolol Hydrochloride)

Hemangiol is indicated for the management of infantile hemangioma, a common benign vascular tumor in early childhood. It may be prescribed when lesions are proliferative, cause functional impairment, or present a risk of complications.

• Treatment of superficial or deep infantile hemangiomas requiring systemic therapy
• Management of hemangiomas affecting vision, airway, or feeding
• Use in cases where rapid tumor regression is clinically desirable
• Adjunct to other therapeutic approaches when monotherapy is insufficient
• Consideration for hemangiomas with ulceration or risk of scarring

Side effects of Hemangiol vary in frequency and severity. Patients should be monitored for any new or worsening symptoms during treatment.

Common

• Fatigue or tiredness
• Mild gastrointestinal upset such as nausea or abdominal discomfort
• Low blood pressure (hypotension)
• Slow heart rate (bradycardia)
• Cold extremities or reduced circulation to hands and feet
• Sleep disturbances or vivid dreams

Serious

• Severe hypotension or syncope
• Marked bradycardia requiring medical attention
• Bronchospasm or worsening asthma symptoms
• Hypoglycemia, particularly in infants with limited feeding
• Signs of heart failure such as swelling or rapid breathing

Before initiating Hemangiol, clinicians should evaluate patient history and monitor specific parameters throughout therapy.

• Assess cardiovascular status, including heart rate and blood pressure
• Review respiratory conditions, especially asthma or chronic bronchospasm
• Monitor blood glucose levels in infants at risk for hypoglycemia
• Conduct baseline liver function tests and repeat as needed
• Evaluate for contraindications such as severe heart block or untreated heart failure
• Counsel caregivers on signs of serious adverse events and when to seek medical care

Hemangiol can interact with several medication classes, influencing its safety and effectiveness.

Avoid

• Other non‑selective beta‑blockers or agents that markedly lower heart rate
• Calcium channel blockers that may exacerbate bradycardia or hypotension
• Certain anti‑arrhythmic drugs (e.g., amiodarone, digoxin)
• Strong CYP2D6 inhibitors that could increase propranolol levels

Use with caution

• Asthma medications, particularly beta‑agonists, due to potential bronchoconstriction
• Antidiabetic agents, as propranolol may mask hypoglycemia symptoms
• Antidepressants such as SSRIs that can affect heart rate
• NSAIDs that may influence renal function when combined with beta‑blockade